Michael M. Morrissey, Ph.D., is President and Chief Executive Officer at Exelixis and a member of the Board of Directors. Under Dr. Morrissey’s leadership since July 2010, the Exelixis team has brought to market three internally discovered medicines aimed at improving the treatment of various forms of cancer, significantly expanded the company’s clinical development and commercial capabilities and markedly strengthened the company’s financial position in order to prepare for the next chapter of its growth. Since joining Exelixis in February 2000, Dr. Morrissey has held positions of increasing responsibility within the company’s discovery and development organizations, including serving as President of Research and Development from January 2007 until July 2010. From 1991 to 2000, he held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. Earlier in his career, Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBA-Geigy Corporation. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University.